More progress, more hope
Improving the lives of those affected by chordoma.

Leading the search for a cure.

Letter from the Executive Director

Dear Friends and Partners,

Like compounding interest, the accumulated impact of our work together over the past 12 years has made possible more progress on more fronts this year than ever before. And, with that progress, more reasons to be hopeful about the future.

In the pages that follow, you’ll see how the pipeline of new treatment options for chordoma continues to grow, from the launch of two new CF-supported clinical trials in 2018 to investments in basic and translational research that are feeding new treatment ideas into that pipeline. You’ll read about our first major foray into new drug discovery, and how our research partners are applying innovative and truly remarkable technologies to develop drugs against brachyury — the Achilles’ heel of chordoma. And, you’ll learn about valuable new resources we rolled out to help make the journey with chordoma feel less lonely and less bewildering.

But, most importantly, this report is a tribute to you — the volunteers, donors, partners, and advisors who make our work possible and propel our mission forward.

Thank you for being a part of this movement. Thank you for helping to set the bar for catalyzing progress against a rare cancer. And thank you for giving all of us affected by chordoma reasons to hope. Because of you, I know chordoma is a solvable problem, and I look forward to continuing to work with you to solve it.

Onward!

Josh Sommer
Co-Founder and Executive Director
13-Year Survivor

---

Table of contents

2  Research
12  Patient Services
16  Uncommon Awards
18  Thank you to our supporters
24  Financials
25  Looking ahead
26  Our team

---

ABOVE: Chordoma patient and medical student, Seth Butler with friends and classmates during his Hike for Chordoma fundraiser.

ON THE COVER: Brooke and Carolyn Laney, parents of a pediatric chordoma patient, at the 2018 International Chordoma Community Conference all the way from Australia.
Having created a vibrant research ecosystem and attracted some of the brightest minds in science, our search for better treatments is progressing at an unprecedented pace. In 2018, we invested a total of $1.2M in research, resulting in significant and measurable progress across every stage of our research roadmap.

### Resource Development
- 25 tumors saved for research through our Biobank
- 1 new cell line validated
- 4 new mouse models validated

### Target Discovery
- 2 grants awarded to discover new epigenetic drug targets

### Therapeutic Discovery
- 3 grants awarded to discover drugs targeting brachyury, the Achilles’ heel of chordoma
- 11 drugs tested in mouse models through our Drug Screening Program
- 1 promising drug (cetuximab) nominated for a clinical trial

### Preclinical Research
- 2 new CF-supported clinical trials launched (afatinib and BN-Brachyury vaccine + radiation)

### Clinical Research
- 2 grants awarded to discover new epigenetic drug targets
- 3 grants awarded to discover drugs targeting brachyury, the Achilles’ heel of chordoma
- 11 drugs tested in mouse models through our Drug Screening Program
- 1 promising drug (cetuximab) nominated for a clinical trial

Most notably, as described in the following pages, we focused on driving progress in four key areas:

1. Bringing research advances to pediatric chordoma
2. Jumpstarting brachyury drug discovery
3. Expanding the pipeline of chordoma clinical trials
4. Expanding the chordoma research network

Read on to learn more »

---

**Bringing research advances to pediatric chordoma**

In 2018, we launched a multi-year Pediatric Chordoma Initiative intended to jumpstart research for this once-neglected subset of the chordoma patient community. Seeded with gifts and pledges totaling $1.3 million, we have already made notable headway:

- **Funded** development of the first pediatric chordoma cell line and PDX model.
- **Tested** eight drugs and combinations in pediatric models through our Drug Screening Program.
- **Ensured** that children 12 and older will be able to participate in forthcoming chordoma clinical trials.
- **Recruited** world class researchers to study pediatric chordoma, including through a breakout session at our biennial International Chordoma Research Workshop dedicated to pediatric chordoma.
- **Worked** with the National Cancer Institute to plan a pediatric and young adult chordoma clinic.

- Above Chordoma survivors, Alli Zellers, Kaitlin Slepian, and Emily Sonner at the 2018 International Chordoma Community Conference.

---

**LEFT**
Participants at a mini-workshop on pediatric chordoma hosted with the National Cancer Institute.
Jumpstarting brachyury drug discovery

The most important insight about chordoma that research has revealed to date is that it has an Achilles’ heel: a protein called brachyury. Not only is brachyury the defining feature of chordoma, but chordoma cells cannot survive without it. With no known function in normal cells, targeting brachyury represents the greatest opportunity to defeat chordoma without harming the patient.

It also turns out that brachyury plays a role in metastasis in a number of other cancers such as breast, lung, colon, and prostate, so therapies against brachyury could have an impact far beyond chordoma. The challenge, however, is that brachyury belongs to a class of proteins called transcription factors, which have historically been considered “undruggable” because they lack the types of nooks, crannies, and crevices to which most drugs bind. Fortunately, several emerging technologies have the potential to overcome this barrier.

In partnership with The Mark Foundation for Cancer Research, we awarded pilot grants to support three projects applying cutting-edge technologies to brachyury drug discovery.

Craig Crews, PhD (Yale University)
Identifying brachyury binders through computational modeling, and attempting to eliminate brachyury by harnessing the innate cellular system for destroying faulty proteins, a process called targeted protein degradation.

Daniel Nomura, PhD (University of California, Berkeley)
Employing novel chemistry techniques to discover molecules that bind strongly and irreversibly to the brachyury protein, providing a foothold for constructing compounds that either directly inhibit brachyury’s function or trigger its degradation. This work is part of a broader project funded by The Mark Foundation for Cancer Research to target “undruggable” proteins implicated in cancer.

Opher Gileadi, PhD (Oxford University)
David Drewry, PhD (University of North Carolina, Chapel Hill)
Charles Lin, PhD (Baylor College of Medicine)
Developing a high-resolution map of the physical structure of the brachyury protein and constructing drugs based on identifying small chemical structures (“chemical fragments”) that interface with subtle features in the protein.

The Foundation’s active role in bringing together research groups with complementary capabilities will probably shorten the time to achieve our goals by at least 50%.

Opher Gileadi, PhD
University of Oxford
Expanding the clinical trials pipeline

Two CF-supported clinical trials opened in 2018, bringing the total number of open trials in our pipeline to five — halfway to our goal of ten by 2020.

The first trial is testing the effectiveness of the FDA-approved targeted therapy afatinib, which blocks a protein called EGFR that plays an important role in driving chordoma. The second is evaluating the effectiveness of an experimental cancer vaccine called BN-Brachyury, which is designed to harness the immune system to attack cells in which brachyury is produced.

---

<table>
<thead>
<tr>
<th>Planning</th>
<th>Active</th>
<th>Results available</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI-6301 with radiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brachyury vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nivolumab with radiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD-1 inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afatinib</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palbociclib</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDK4/6 inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BN-brachyury vaccine with radiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncolytic bacteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autologous tumor vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR antibody</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Looking for a clinical trial that may be right for you?

Our Clinical Trials Catalogue lists all chordoma-specific trials as well as all other trials deemed relevant to chordoma patients by our Medical Advisory Board (MAB). It currently includes information on 17 trials worldwide.

chordoma.org/clinical-trials

---

Chris Heery, MD
Chief Medical Officer, Bavarian Nordic

The challenges of doing research in rare cancers often deter companies from investing in developing drugs for these patient populations, despite the significant unmet need. But the Chordoma Foundation has made it feasible for companies like ours to pursue drug development for this rare tumor type. Working with the Foundation was critical to enabling us to open and quickly enroll patients into the BN-brachyury vaccine trial.”
Expanding the chordoma research network

After more than a decade of cultivating interest in chordoma and attracting researchers into the field, today, we are grateful to be working with a network of more than 350 research collaborators and 12 pharmaceutical and biotech companies. And, as the bleeding edge of chordoma research continues to expand into new areas, we are working proactively to recruit the most talented scientists in those areas to turn their attention to chordoma.

Expanding chordoma research in Canada

Through a joint grants program with the Canadian Cancer Society, we awarded two $150,000 grants in 2018 to outstanding physician scientists whose work is breaking new ground in understanding chordoma biology and identifying new treatment approaches.

- **Dr. Stephen Yip, MD, PhD (BC Cancer Agency)** is working to identify epigenetic drugs that can make chordoma more susceptible to immune attack and thus make immunotherapies more effective.

- **Dr. Gelareh Zadeh, MD, PhD (University of Toronto)** is undertaking the largest study to-date to characterize epigenetic alterations in chordoma and identify new epigenetic targets.

Currently funded researchers

- **Cameron Brennan, MD, PhD**  
  Memorial Sloan Kettering Cancer Center

- **Craig Crews, PhD**  
  Yale University

- **David Drewry, PhD**  
  University of North Carolina

- **Adrienne Flanagan MD, PhD**  
  University College London

- **Hans Gelderblom, MD, PhD**  
  Leiden University Medical Center

- **Opher Gileadi, PhD**  
  Oxford University

- **Michael Kelley, MD**  
  Duke University

- **Michael Lim, MD**  
  Johns Hopkins

- **Charles Lin, PhD**  
  Baylor College of Medicine

- **Dan Nomura, PhD**  
  UC Berkeley

- **Slim Sassi, PhD**  
  Massachusetts General Hospital

- **Stuart Schreiber, PhD**  
  Broad Institute of Harvard and MIT

- **Yoshiya (Josh) Yamada, MD**  
  Memorial Sloan Kettering Cancer Center

- **Stephen Yip, MD, PhD**  
  BC Cancer Agency

- **Gelareh Zadeh, MD, PhD**  
  University of Toronto

*2018 Grantees
- Funded through partner organization
Uniting the global chordoma community

In March, a record number of participants joined us in Boston for the sixth International Chordoma Research Workshop (ICRW) and International Chordoma Community Conference (ICCC).

Together, these two conferences serve as the principal gathering points for the worldwide chordoma research and patient communities, providing a unique opportunity to forge relationships and share the latest research and treatment advances. Hosted back to back, they also serve as an important bridge between the researchers working to find better treatments and the individuals who stand to benefit from their work.

140 doctors and scientists
100 patients and caregivers
10 countries
70 institutions
Patient Services

This year, a record number of patients and families turned to the Foundation for information, guidance, and support through their journey with chordoma. To better meet their needs, we developed a host of new educational resources and launched a new, private online community called Chordoma Connections to facilitate more peer-to-peer knowledge sharing and support among patients and caregivers.

**560+**
Patient Navigation cases served

**6,300+**
views of our Doctor Directory

**200K**
views of “Living with chordoma” section of our website

---

Expert Recommendations for the Treatment of Recurrent Chordoma

Our newest educational booklet helps patients and caregivers facing a recurrence learn about and act upon evidence-based treatment guidelines developed by top chordoma experts.

[chordoma.org/educational-materials](http://chordoma.org/educational-materials)

---

Aaron's story

Aaron McMahon, a sports-loving teen from County Cork, Ireland, was diagnosed with a skull base chordoma in March of 2017 at just 16 years old.

After undergoing surgery in Ireland and radiation in Germany, Aaron and his family were optimistic chordoma would be behind them. So, when, just a few months later, his tumor started growing again, they were devastated. Aaron’s doctors told the family there was nothing more they could do.

But at 16 years old, with his whole life ahead of him, **Aaron and his parents refused to give up hope**. Instead, they made contact with our Patient Navigators who helped the family understand their treatment options, connect with fellow patients, and meet Dr. Paul Gardner, a neurosurgeon and chordoma expert at the University of Pittsburgh Medical Center (UPMC).

After learning that he was, in fact, a candidate for surgery, Aaron and his family were elated. They felt as if he had been granted a second chance. **Aaron’s whole community rallied behind him**, launching an all-out fundraising campaign to get him the care he needed. Through fundraisers, personal donations, and even a music video, they raised over €100,000 within a matter of months to send Aaron to Pittsburgh.

In June of 2018, Aaron underwent surgery at UPMC to remove the tumor that his local doctors told him was inoperable. Amazingly, they were able to remove the entire tumor, and Aaron made it through surgery with flying colors. Following surgery, Aaron’s diagnosis was revised to chondrosarcoma, a tumor for which chordoma is often misdiagnosed. Thanks to the help he received, Aaron is now back in Ireland preparing to start college and looking forward to a bright future.
I am so proud of the Foundation’s work to build this community and so grateful for the opportunity to serve as a moderator. Though it may seem like that role is about helping others, I have found that it is helping me, too. After losing my husband to chordoma, it has been a privilege to share connections with others who have experienced some of the same things I have, and help each other move forward together.”

Kris Stahl
Chordoma Foundation Peer Guide and co-moderator of Chordoma Connections

Since launching in January, more than 650 patients and caregivers worldwide have joined the conversation in Chordoma Connections, the Foundation’s private online community. They come from many different backgrounds, countries, and cultures, but they all share one thing in common — the experience of having had their lives forever changed by chordoma.

Chordoma Connections offers a space where individuals affected by chordoma can turn to ask questions, share experiences, and get support from others who understand and have walked their same path. From insights on pain management, systemic therapy, side effects of treatment, or how to cope with survivorship, it’s all there.

community.chordoma.org

650+
members

36
states in the U.S.

50
countries

300+
discussion threads

8
private groups
Uncommon Awards

Our Uncommon Awards recognize members of our community who exemplify the qualities necessary for success in the fight against chordoma.

Uncommon Action
Chris Jones
For his consistent teaching, guidance, and support of fellow patients and caregivers as a Peer Guide, a moderator of the Chordoma Survivors group on Facebook, and Chair of our Community Advisory Board.

“When my daughter’s disease ultimately ran its course, it didn’t need to – or at least not so soon – had it been properly diagnosed initially. I remain committed to the Chordoma Foundation and to helping them improve the lives of people impacted by chordoma, and provide patients and families with support in navigating this challenging journey.”

Uncommon Champion
Steven Mandel
For his extraordinary fundraising efforts through #TeamChordoma, which have raised nearly $300,000 for the Foundation since 2014.

“Five years ago, when we started our half marathon fundraiser, it was just me and four friends. Today, we have more than 60 runners on #TeamChordoma. This event has become a staple at the Foundation, and I hope it serves as a grassroots model for many others in the community to kick-start their own #TeamChordoma fundraiser.”

Uncommon Champions
Team Fat Boys
Slim Sisters
For raising more than $300,000 in honor of one of their own — chordoma survivor Todd Balf — to support cutting edge chordoma research in the lab of Cigall Kadoch at Dana-Farber Cancer Institute.

“Although I joked that having chordoma was proof of what I’d always maintained – that I was one in a million – the recovery was harder than I could have ever imagined. In addition to my family, one of the things that most motivated me in my recovery was to try to get back on the bicycle and ride again. Being on the bike, surrounded by the whole team, felt like the best normal ever. To have that kind of support was incredible, and something I’ll never forget.”

— Todd Balf, chordoma survivor

Uncommon Collaboration
Ulm and Heidelberg Chordoma Research Teams
For working together to make great strides in chordoma research, including the discovery of a new therapeutic target, and, most recently, launching a clinical trial for chordoma patients.

“I am truly amazed by the collaborative spirit that the Foundation fosters in this field. Our team in Heidelberg is happy to be a part of it, and we look forward to continuing to make progress with our friends and colleagues at Ulm University.”

— Stefan Fröhling, Heidelberg University Chordoma Research Team

Uncommon Insight
Opher Gileadi, Oxford University
For solving the crystal structure of brachyury, a vital step both toward understanding how brachyury drives chordoma and developing new therapies that target brachyury.

“Normally, this type of discovery would take months to reach publication, and then maybe years to be exploited. But with the help of the Foundation, we immediately formed a network of collaborating experts in chemistry, cell biology, crystallography, and disease biology, and we’re already moving forward to discover inhibitors of brachyury.”

Uncommon Perseverance
Joel Beckman
For his extraordinary contributions to the Foundation as a leader on the Board of Directors, Chair of the Development Committee, mentor and guide to fellow patients, successful fundraiser, and transformational donor.

“Chordoma has been a major battle for me and I’m incredibly happy to be here nine years after being diagnosed, during which time I have seen both of my sons married and my two grandchildren born. The Chordoma Foundation is saving lives and improving the lives of so many individuals confronting the disease. I’m truly amazed when I look at the progress the Foundation has helped to achieve in such a short time. And I’m so proud that I’m able to play a role in such an extraordinary organization.”
Thank you for your support

We are filled with gratitude for all you have done for chordoma patients and families over the past year. You gave your time, your money and your heart to this uncommon community, creating a great and lasting impact.

$2.5M contributed

18 community fundraising events

1,870+ donors around the world

2018 Online Fundraising Champions

<table>
<thead>
<tr>
<th>Name</th>
<th>Since</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gail Baker</td>
<td>2018</td>
</tr>
<tr>
<td>Daniele Bananto</td>
<td>2018</td>
</tr>
<tr>
<td>Matt Berger</td>
<td>2018</td>
</tr>
<tr>
<td>Sharon Berlan</td>
<td>2008</td>
</tr>
<tr>
<td>Dusty Bowenkamp</td>
<td>2013</td>
</tr>
<tr>
<td>Sue &amp; Gene Brenneman</td>
<td>2018</td>
</tr>
<tr>
<td>Seth Butler</td>
<td>2018</td>
</tr>
<tr>
<td>Christopher &amp; Stephen Capuzzi</td>
<td>2017</td>
</tr>
<tr>
<td>Nicholas Carr</td>
<td>2018</td>
</tr>
<tr>
<td>David Drewry</td>
<td>2018</td>
</tr>
<tr>
<td>Christina Ciocca Eiler</td>
<td>2018</td>
</tr>
<tr>
<td>The Henry G. Ciocca Champion Fund</td>
<td>2018</td>
</tr>
<tr>
<td>Stephanie Finley</td>
<td>2018</td>
</tr>
<tr>
<td>Aimee Howell</td>
<td>Team Stephen 2018</td>
</tr>
<tr>
<td>Norma Jones</td>
<td>2009</td>
</tr>
<tr>
<td>Vanessa King</td>
<td>2018</td>
</tr>
<tr>
<td>Michael Potempa</td>
<td>2013</td>
</tr>
<tr>
<td>Justin Remsen</td>
<td>2018</td>
</tr>
<tr>
<td>Colleen Riccomini</td>
<td>2018</td>
</tr>
<tr>
<td>Colleen Riccomini</td>
<td>2018</td>
</tr>
<tr>
<td>Colleen Riccomini</td>
<td>2018</td>
</tr>
<tr>
<td>Rachel Lichte</td>
<td>30-for-30 Birthday Challenge 2017</td>
</tr>
<tr>
<td>Bart Salant</td>
<td>2018</td>
</tr>
<tr>
<td>Jaclyn Salant</td>
<td>2018</td>
</tr>
<tr>
<td>Matt Sauerhoff</td>
<td>2016</td>
</tr>
<tr>
<td>Dan Sauerhoff</td>
<td>2018</td>
</tr>
<tr>
<td>Maureen Schroer</td>
<td>2013</td>
</tr>
<tr>
<td>Robin Seitz</td>
<td>2018</td>
</tr>
<tr>
<td>Emily Sommer</td>
<td>2018</td>
</tr>
<tr>
<td>Kristin Stahl</td>
<td>The Marty Stahl Champion Fund 2018</td>
</tr>
<tr>
<td>Julie and Jeremy Trask</td>
<td>2018</td>
</tr>
<tr>
<td>Jaclyn Weissman &amp; Zach Grauman</td>
<td>2018</td>
</tr>
</tbody>
</table>

2018 Community Fundraising Events

<table>
<thead>
<tr>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10th Annual St. Paul’s Michael Galluccio Memorial Golf Outing</td>
<td>Mark Galluccio and Zach Feigman, Glen Cove, NY</td>
</tr>
<tr>
<td>Blockbuster Bowling Benefit</td>
<td>Jeff Schilling, Kansas City, MO</td>
</tr>
<tr>
<td>Brooklyn Half Marathon</td>
<td>Steven Mandel, London, UK</td>
</tr>
<tr>
<td>Dawson’s Circle of Hope 5K</td>
<td>Susan Craeger, Geneva, FL</td>
</tr>
<tr>
<td>Dress Down Day</td>
<td>Lynette Nelson, Clifton, NJ</td>
</tr>
<tr>
<td>Hike To Find A Cure For Chordoma</td>
<td>Seth Butler, Pownal, ME</td>
</tr>
<tr>
<td>Infinity Fitness Day</td>
<td>Todd Balf, Beverly, MA</td>
</tr>
<tr>
<td>Make Mr. Whelan Look Silly</td>
<td>Colleen Riccomini, West Sayville, NY</td>
</tr>
<tr>
<td>No Shave November</td>
<td>Nicholas Carr, Willimstown, PA</td>
</tr>
<tr>
<td>Olde Fashioned Colonial Christmas Home Tour</td>
<td>Gene and Sue Brenneman, PA</td>
</tr>
<tr>
<td>Operation Support &amp; Recover Ride</td>
<td>Rik Karena, Queensland, AU</td>
</tr>
<tr>
<td>Pan-Mass Challenge</td>
<td>Maggie Bates, Kansas City, MO</td>
</tr>
<tr>
<td>Pub Crawl for Chordoma</td>
<td>Colleen Riccomini, West Sayville, NY</td>
</tr>
<tr>
<td>Picnic at the Park</td>
<td>Colleen Riccomini, West Sayville, NY</td>
</tr>
<tr>
<td>Skyline’s 10th Annual Charitable Gold Classic</td>
<td>The Skyline Charitable Foundation, Long Island City, NY</td>
</tr>
</tbody>
</table>

18            CHORDOMA FOUNDATION 2018 ANNUAL REPORT            19
Accelerators Circle

Formed in 2018, the Accelerators Circle recognizes donors who make a gift of $25,000 or more over a 3-year period to speed the pace of progress.

We are deeply grateful to the following individuals, families, and organizations who joined the Accelerators Circle in 2018:

Leader
$500,000+
Anonymous (3)
The Beckman Family Foundation

Benefactor
$250,000 – $499,999
Mark Foundation for Cancer Research

Patron
$100,000 – $249,999
Anonymous
Richard and Susan Friedman
Esta Stecher

Supporter
$50,000 – $99,999
Anonymous
Joe and Christine McGovern
Grace and Andrew Schoellkopf

Friend
$25,000 – $49,999
Anonymous (2)
The Alpert Family Foundation
Celtene
Dawson’s Circle of Hope

$250K+
Anonymous
The Beckman Family Foundation
Mark Foundation for Cancer Research

$100K–249,999K
Anonymous (3)
Richard and Susan Friedman
Esta Stecher

$25K–99,999K
Anonymous
The Alpert Family Foundation
The Cedar Street Foundation
Collin’s Circle of Hope

$10K–24,999K
Anonymous (2)
Bavarian Nordic A/S
John and Myrna Blume
Boehringer Ingelheim
Sherry Brown-Marfuggi
Chordoma Foundation Europe
Charles and Marna Davis Foundation
Hester M. Digges Trust U/A
Illinois Tool Works

2018 Donors

We’re grateful to the following donors who made our work possible in 2018.

Goldman Sachs Gives: The Barry and Rochelle Kaplan Fund
The Robert and Sydney Kindler Foundation
Heather Lee and Steve Straus
Steven Mandel
Massachusetts General Hospital Cancer Center
SBES Client Consolidated Charitable Foundation, Inc
Chandranath and Sharmila Sen

$1K–4,999K
Anonymous (5)
AmazonSmile Foundation
American Century Investments
Ameriprise Financial
Yoram Amiga
Victoria Anderson
The Norman and Mary Anderton Charitable Fund
Shelba Barnes
Jaynee and Eric Beckman Family Fund
Benevity Community Impact Fund
Berg Family Fund
Stanley, Marion, Paul and Edward Bergman Family Foundation
Bespoke Partners, Inc.
David Biondi
Steve and Erin Bishop
Baltimore County Employees Federal Credit Union Board of Directors
Robert and Teresa Boccanfuso
Gene and Sue Brenneman
John and Renee Butler
Douglas and Jen Call
Ann Marie Castenfelt
John Cochrane
Kenny and Mona Cohen
Samuel Cohen
Collins Electric Co.
William and Sharon Connelly
Robert and Maureen Cooper
Frank Courtney

The Chordoma Foundation was a voice in the wilderness for our family after my husband Joe was diagnosed. We benefited so much from their information and encouragement – especially their help finding experienced doctors, which made all the difference in Joe’s outcome and recovery. Getting that help at such a frightening time gave us hope, and hope and gratefulness are powerful motivators. That’s why we joined the Accelerator’s Circle. Because we know that a strong Chordoma Foundation means a stronger and healthier chordoma community. And that’s an investment worth making.”

Megan Stewart
Wife of chordoma patient
Joe Stewart
Leslie and Rhoda Mandel
Thomas and Holly Lund
Robert and Kit Lennon
Kenneth and Frankie Lee
Ira and Lillian Langsan Fund
Ingemar and Diane Lane
KPMG
Michael and Loida Knox
Kirkland
in Memory of George and Muriel
Kenneth Wilson Family Foundation
The Judy Kirkland and James
Jeffrey Kaufman
Carol Kary
Ken and Cathy Katz Foundation
Jeffrey Kaufman
The Judy Kirkland and James
Kenneth Wilson Family Foundation in Memory of George and Muriel Kirkland
Michael and Loida Knox
KPMG
Ingeamar and Diane Lane
Ira and Lillian Langsan Fund
Kenneth and Frankie Lee
Robert and Kit Lennon
Irene Loeb
Lucey Charitable Foundation
Thomas and Holly Lund
Leslie and Rhoda Mandel
Maryland Proton Treatment Center
Cynthia McFees
Linda Mirels
Alexander Nadaner
Bruce and Lynette Nelson
Victor and Denise Nesi
Northwestern University Feinberg School of Medicine
Daniel and Jane Och Charitable Trust
Michael and Gillian Parrish
James and Kathleen Patton
Ponsinelli
Michael and Jo-Ann Rapaport
Ray Underhill Foundation, Inc.
Maria Pia Ruffilli
Gary and Karen Sain
Robert and Inger Schollkraft
Madhav Shenoy
Sherwood Forest Boys & Girls Summer Camp
The Skyline Charitable Foundation Inc.
Gregg Slepian
David Smyth and Julie Song
Josh Sommer and Rachel Lichte
Young-dahl and Juliet Kim Song
Paula Song and Stephen Gazda
Judith Sprague
Steve and Kimberli Sterling
Robinson Strauss and Sharon Berlan
The Steve Sullivan and Erin McKeen Fund
Barry Swidler
John and Heather Thieren
Claudio and Mirna Umaschi
University of Florida Proton Therapy Institute
University of Pennsylvania Health System
University of California Los Angeles Health
Nicholas Vantzelde and Lauren Erb
Veritas Foundation Fund
Joe and Allison Villinski
Terry and Colleen Wilkins
$500–999
Anonymous (5)
Randy and Patricia Akers
American Express Foundation
Michael Arens
Thomas and Nicole Armentrout
Kurtis Bachman
Paul and Karen Baer
Walter Bananto
Scott Barber and Jennifer Schwartz
Warren Barrett
Scott Bartholow
David and Laura Barton
Michele Barton
Karen Barwick
Jonathan and Margaret Bates
Mindy Berry
Sharon Berry
Dusty Bowenkamp
Alicia Brown
Nancy Buckman
Carol Bunt
Kelly Campbell
Peter Casanave and Naomi Nemtzow
Peter and Sharon Catto
Yen-Lin Chen
Michael Ciocca
Rita Ciocca
Cohen Feeley Altermose & Rambo, P.C.
Karen Cox
Daniel Dempsey and Barbara Seneha
Kate Egan
Marjory Eller
Enterprise Bank & Trust
Lynn Etheredge Fund
Oliver Evans
Peter Fang
Russell and Virginia Flaim
Jeannine Fuchs
Gregory and Diane Fuchs
Cink Fundraising
Joan Funk
Andrew Gaasch
John Gally
William and Beverly Griffin
Arthur Haggar
Celina Hecht
Jeff and Diane Hewitt
Infinity Fitness AZ, LLC
Julia Jernigan
The Suzanne Nora Johnson & David G Johnson Foundation
Jeremy Johnson
Mark Konnick
Adalbert Kath
Jerald and Albertina Kuhn
Tzuchin Lee
Kara Leibel
Levy Holm Pellegrino & Drath LLP
Kenny Li
Richard and Susan Lichte
Andrew Little
MarksNelson LLC
Dolores Martinez
Jordan Marye
George Masnick and Reisa Kahn
Brea and Chris McCormley
Robert and Polly McCrea
Family Fund of the Minneapolis Foundation
Merck Foundation
Francis J. and Mary A. Meyer Charitable Fund
Emery Miller
Monsanto Matching Gift Program
Victoria Moran
Thomas Mass and Janie Deal
Arlynn Mucley
Christine Newfrock
Nancy Prendergast and Augusto Pichard
Red Top Foundation
Alicia Reid
J. Robert and Nora Reinhardt
Scott Renner
Dietmar and Dorothy Riccomini
James Rittinger
Richard and Stacy Rosenthal
Adriane Rothstein and Mark Billy
Hans and Mary Lou Saebey
Sayville Union Free School District
The Shepard Broad Foundation, Inc.
Theodore and Katherine Shults
Scott Silverthorne
Gary Simon
Scott Smiley
Bruce and Maureen Smith
Matthew and Laura Soule
Mike Staveris
Strategic Enhancement Group Inc
Robert Switzer
Takeda Pharmaceuticals NA, Inc.
Employee Giving Program
Jeffrey and Janis Tillman
Andrew Tinn
Jeremy and Julie Trask
University of New England
Patty Vaughn
David and Toni Walton
Scott and Joanne Winters
Susan Woodman
We have made every attempt to ensure the accuracy of our donor list and we regret any errors or omissions. Please contact us at feedback@chordoma.org to correct any inaccuracies.
Financials
Audited statement of activities for the year ended December 31, 2018

<table>
<thead>
<tr>
<th>Revenue and support</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$ 2,314,783</td>
</tr>
<tr>
<td>In-kind contributions</td>
<td>166,405</td>
</tr>
<tr>
<td>Program service revenue</td>
<td>11,150</td>
</tr>
<tr>
<td>Interest</td>
<td>4,180</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td><strong>$ 2,496,518</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>$ 1,666,722</td>
</tr>
<tr>
<td>Management and general</td>
<td>306,030</td>
</tr>
<tr>
<td>Fundraising</td>
<td>439,268</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$ 2,412,020</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in net assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, beginning of year</td>
<td>3,434,984</td>
</tr>
</tbody>
</table>

| Net assets, end of year                          | **$ 3,486,695**|

A copy of our 2018 IRS Form 990 and audited financial statements are available at chordoma.org/financials

Looking ahead

Thanks to your investment and support, we’re on the cusp of some really big steps forward, particularly in the development of new therapies.

A growing pipeline of better chordoma treatments is on the way, and those facing the disease today now have a deep trove of trusted resources and support systems to aid in the journey.

But we won’t rest until everyone affected by chordoma is able to overcome the disease and maintain their quality of life. Here’s our plan of attack for 2019:

**2019 Priorities**

- **More support for patients and families**, including new educational content, new translations to reach more people worldwide, and more in-depth support from our Patient Navigation Service.

- **Greater progress in clinical trials**, including increasing patient participation, completing enrollment milestones for on-going CF-supported trials, and launching at least one new trial.

- **Expanded investment in brachyury drug discovery**, including follow-on funding for current collaborators whose research has proven successful, and new grants for pre-vetted, high-impact proposals.

- **New investments in cutting-edge science** aimed at attacking chordoma through epigenetics and immunotherapies.

We look forward to working with you to make this progress possible!
Our team

Our staff

Josh Sommer
Executive Director

Daniel Baroff
Development Manager

Patty Cogswell
Manager of Research

Larry Gottschalk
Operations Coordinator

Chase Hinnant
Patient Services Coordinator

Joan Levy, PhD
Director of Research

Shannon Lozinsky, MSW
Director of Patient Services

Breanna McCormley
Director of Development

Jennifer Roeder
Marketing and Communications Manager

Tammy Silverthorne
Director of Operations

Gillian Parrish
Communications Consultant

Board of Directors

Andrew Schoelkopf
Chair

Joel Beckman
Vice Chair

Ingemar Lanevi
Treasurer

David Drewry, PhD

Steven Mandel
Shreyas Patel, MD

David Sandak
Christy Shaffer, PhD

Kerry Shad, JD*

Josh Sommer
Paula Song, PhD

Board committees

FINANCE

Ingemar Lanevi
Chair

Mark Ricca
Andrew Schoelkopf

RESEARCH

Kurt Bachman, PhD
Jeffrey Collins, PhD
David Drewry, PhD
Shreyas Patel, MD
William Phelps, PhD
David Sandak
Chandra Sen, MD
John Therien, JD

PATIENT SERVICES

Paula Song, PhD
Chair
Karen Cox, PhD, RN
Vickie Leff, LCMSW**

Michael O’Brien, MSW, LICSW

DEVELOPMENT

Joel Beckman
Chair
Anne Noel Dawson
Steven Mandel
Andrew Schoelkopf
Joe Villinski

NOMINATING

Joel Beckman
Chair
Edward Les, MD
Andrew Schoelkopf
Christy Shaffer, PhD

EXECUTIVE

Andrew Schoelkopf
Chair
Joel Beckman
Ingemar Lanevi
David Sandak
Kerry Shad, JD*

Scientific Advisory Board

David Drewry, PhD
Adrienne Flanagan, MD, PhD
Fran Hronicek, MD, PhD
Michael Kelley, MD
Paul Meltzer, MD, PhD
Deric Park, MD

Medical Advisory Board

Shreyas Patel, MD
Chair
Greg Cota, MD, PhD
Tom DeLaney, MD
Paul Gardner, MD
Hans Gelderblom, MD, PhD
Ziya Gokaslan, MD
Minal Gounder, MD
Christopher Heery, MD
Fran Hronicek, MD, PhD
Chandra Sen, MD
Silvia Stacchiotti, MD
Katie Thornton, MD
Josh Yamada, MD

Community Advisory Board

Chris Jones
Chair
Edward Les, MD
Medical Liaison
Sue Brenneman
Susan Garbett
Steven Golick
Caroline Kooy
Maureen LaForge
Heather Lee, PhD
Steven Mandel
Joe McGovern
Jeff Schilling
Tim Zellers

*Through November 2018
**Through June 2018

Our staff outside the Broad Institute in Cambridge, MA. Not pictured: Larry Gottschalk and Jennifer Roeder.
I have been so impressed with what the Chordoma Foundation and the chordoma community have accomplished together. It gives me great hope that the years ahead will be even more promising.”